Gender-specific analyses indicate that men with major depression or less severe symptoms at baseline had no significant increase in risks of becoming unemployed subsequently.
At t48, Cys-C levels in the ADR and the CON group had increased significantly in comparison with baseline levels, whereas no significant increase in this parameter was observed in the MIL group.
Although the time spent on ANC increased in Tanzania and Ghana after the eCDSS implementation as compared to baseline, overall there was no significant increase in time used for ANC activities (0.51 min, p=0.06 in Ghana; and 0.54 min, p=0.26 in Tanzania) as compared to the control sites without the eCDSS.
Of interest is the different dynamics of changes in HDL cholesterol (although the difference between groups was not significant): whereas it increased in the control group from baseline to 6 months with no significant increase in either period, it increased in the experimental group only after the addition of exercise.
Patients with COPD treated with simvastatin had higher concentrations of IL-10 in sputum supernatants compared with the baseline levels, whereas there was no significant increase of IL-10 in patients with COPD who received placebo (median [IQR], 28.8 pg/mL [17.5-41.7 pg/mL] vs 7.2 pg/mL [5.9-9.0 [5.9-9.0pg/mL]1; 8.3 Pg/mL [6.5-10.0 pg/mL] vs 8.1 pg/mL [6.6-9.5 pg/mL], P =.78, respectively).
While Bonferroni post-hoc comparison in the control group indicated a significant increase in resilience scores from baseline to post-test (mean difference = -16.04, p < 0.05), there was no significant increase from baseline to follow-up (mean difference = -10.54, p = 0.143) and from post-test to follow-up (mean difference = 5.50, p = 0.650).
Gene carriers showed no significant increase from baseline in avoidant thoughts, but there was an increase in intrusive thoughts at 1 month only compared to baseline (P<0.001).
During headache attacks, we registered a significant PRL increase from baseline, only in patients of the group A (attacks vs baseline: 150.6 ± 16.8 vs 118.6 ± 10.8 ng/mL; p < 0.005), while in the group B, no significant increase of PRL levels from baseline were registered in all patients (attacks vs baseline: 108.7 ± 8.7 vs 106.9 ± 9.7 ng/mL; p = 2.5).
We restricted these analyses to the dHPC because the previous analysis found no significant increase of vHPC above baseline during the radial maze tasks.
The log scale insert illustrates the seasonality of the ILI baseline and a significant increase in baseline ILI diagnoses throughout the pandemic period.
